Drug Type Bispecific antibody |
Synonyms LEAD462 |
Target |
Action agonists, inhibitors, stimulants |
Mechanism TNFR agonists(Tumor necrosis factor receptor agonists), Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedDiscovery |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Breast Cancer | Discovery | Spain | 01 Sep 2022 | |
| Colorectal Cancer | Discovery | Spain | 01 Sep 2022 | |
| Kidney Neoplasms | Discovery | Spain | 01 Sep 2022 | |
| Liver Cancer | Discovery | Spain | 01 Sep 2022 | |
| Melanoma | Discovery | Spain | 01 Sep 2022 | |
| Non-Small Cell Lung Cancer | Discovery | Spain | 01 Sep 2022 | |
| Stomach Cancer | Discovery | Spain | 01 Sep 2022 | |
| Uterine Cervical Cancer | Discovery | Spain | 01 Sep 2022 |






